Vesnarinone causes oxidative damage by inhibiting catalase function through ceramide action in myeloid cell apoptosis - PubMed (original) (raw)
Vesnarinone causes oxidative damage by inhibiting catalase function through ceramide action in myeloid cell apoptosis
Tadakazu Kondo et al. Mol Pharmacol. 2002 Mar.
Abstract
Vesnarinone is an effective inotropic agent for treating congestive heart failure, but its clinical usage is restricted because of the severe side effect of agranulocytosis. In myeloid HL-60 cells, vesnarinone increased the intracellular content of a proapoptotic lipid mediator, ceramide, in a time- and dose-dependent manner. Vesnarinone-induced apoptosis was significantly enhanced by simultaneous treatment with a cell-permeable N-acetyl sphingosine (C2-ceramide). Treatment with neither vesnarinone, C2-ceramide, nor simultaneously with vesnarinone and C2-ceramide caused a marked increase of reactive oxygen intermediates (ROI) generation measured by the 2',7'-dichlorofluorescin method. However, oxidative damage judged by the production of lipid peroxidates and the nitroblue tetrazolium-reducing ability were enhanced more significantly by simultaneous treatment with vesnarinone and C2-ceramide than by vesnarinone alone. Moreover, vesnarinone inhibited catalase function both at the protein and activity level, and this inhibition was synergistically enhanced by C2-ceramide, and vesnarinone-induced oxidative damage and apoptosis were significantly suppressed by treatment of HL-60 cells with purified catalase. C2-ceramide enhanced vesnarinone-induced inhibition of the ROI-scavenging enzyme catalase at the levels of protein and activity in HL-60 cells; in contrast, however, vesnarinone did not induce ceramide generation, oxidative damage, or catalase depletion in HL-60/ves cells, where vesnarinone could not induce apoptosis. Taken together, the results suggest that vesnarinone induces myeloid cell apoptosis by increasing oxidative damage via ceramide-induced inhibition of catalase function.
Similar articles
- Ceramide increases oxidative damage due to inhibition of catalase by caspase-3-dependent proteolysis in HL-60 cell apoptosis.
Iwai K, Kondo T, Watanabe M, Yabu T, Kitano T, Taguchi Y, Umehara H, Takahashi A, Uchiyama T, Okazaki T. Iwai K, et al. J Biol Chem. 2003 Mar 14;278(11):9813-22. doi: 10.1074/jbc.M201867200. Epub 2003 Jan 2. J Biol Chem. 2003. PMID: 12511568 - Control of ceramide-induced apoptosis by IGF-1: involvement of PI-3 kinase, caspase-3 and catalase.
Kondo T, Kitano T, Iwai K, Watanabe M, Taguchi Y, Yabu T, Umehara H, Domae N, Uchiyama T, Okazaki T. Kondo T, et al. Cell Death Differ. 2002 Jun;9(6):682-92. doi: 10.1038/sj.cdd.4401019. Cell Death Differ. 2002. PMID: 12032677 - Vesnarinone exhibits antitumor effect against myeloid leukemia cells via apoptosis.
Fujiwara H, Arima N, Otsubo H, Matsushita K, Hidaka S, Arimura K, Kukita T, Yamaguchi K, Tanaka H. Fujiwara H, et al. Exp Hematol. 1997 Oct;25(11):1180-6. Exp Hematol. 1997. PMID: 9328455 - Vesnarinone: a potential cytokine inhibitor.
Sasayama S, Matsumori A. Sasayama S, et al. J Card Fail. 1996 Sep;2(3):251-8. doi: 10.1016/s1071-9164(96)80048-0. J Card Fail. 1996. PMID: 8891863 Review. - Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety.
Furusawa S, Ohashi Y, Asanoi H. Furusawa S, et al. J Clin Pharmacol. 1996 May;36(5):477-81. doi: 10.1002/j.1552-4604.1996.tb05035.x. J Clin Pharmacol. 1996. PMID: 8739027 Review.
Cited by
- Functional and structural changes of human erythrocyte catalase induced by cimetidine: proposed model of binding.
Yazdi F, Minai-Tehrani D, Jahngirvand M, Almasirad A, Mousavi Z, Masoud M, Mollasalehi H. Yazdi F, et al. Mol Cell Biochem. 2015 Jun;404(1-2):97-102. doi: 10.1007/s11010-015-2369-3. Epub 2015 Mar 5. Mol Cell Biochem. 2015. PMID: 25739358 - Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis.
Miyaji M, Jin ZX, Yamaoka S, Amakawa R, Fukuhara S, Sato SB, Kobayashi T, Domae N, Mimori T, Bloom ET, Okazaki T, Umehara H. Miyaji M, et al. J Exp Med. 2005 Jul 18;202(2):249-59. doi: 10.1084/jem.20041685. Epub 2005 Jul 11. J Exp Med. 2005. PMID: 16009715 Free PMC article. - Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
Bertolet BD. Bertolet BD. Drug Saf. 2004;27 Suppl 1:11-8. doi: 10.2165/00002018-200427001-00003. Drug Saf. 2004. PMID: 15293849 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous